The Brentuximab vedotin is medically approved for the treatment of Hodgkin lymphoma, cutaneous T-cell lymphoma and systemic Anaplastic Large Cell Lymphoma.

Brentuximab vedotin is used to treat various cancers, including classical Hodgkin lymphoma (both newly diagnosed and relapsed), systemic anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, cutaneous T-cell lymphoma, and CD30-expressing mycosis fungoides, all in combination with other therapies.

Brentuximab vedotin can be administered only as an intravenous injection into a vein by your physician in a hospital setting. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition.

Brentuximab vedotin can cause serious side effects, including low blood cell counts, which can increase your risk of infection, bleeding, or bruising; tingling, numbness, or burning pain in your hands or feet; lung problems like cough, shortness of breath, or wheezing; high blood sugar; allergic reactions including rash, hives, swelling of the face, throat, or tongue, difficulty breathing; and serious skin reactions.

Brentuximab vedotin could develop a serious brain infection called progressive multifocal leukoencephalopathy (PML), leading to disability or death. Your blood cell counts might drop, increasing your risk of infections, bleeding, or bruising. Your doctor will monitor your blood regularly. You could experience tingling, numbness, or burning pain in your hands or feet.

Watch for new or worsening problems with speech, thought, vision, or muscle movement after taking Brentuximab vedotin, and tell your doctor immediately. Avoid activities that could increase your risk of getting sick, such as being around people with infections. Wear comfortable shoes and avoid activities that put pressure on your nerves. Report any bleeding or bruising, even minor ones.

During the course of treatment with Brentuximab vedotin and for a specified period afterward (up to 6 months following the last dose), men are advised not to father a child. This precaution is taken to minimize any serious risks to the unborn child that may arise from exposure to the medication.

1. Takeda Pharma A/S, Electronic Medicines Compendium (EMC), [Revised on June 2022] [Accessed on 11 August 2023], https://www.medicines.org.uk/emc/files/pil.2859.pdf
2. Adcetris 50mg injection. Macmillan Cancer Support, [Revised on 1 July 2022], [Accessed on 11 August 2023], www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/brentuximab
3. Adcetris, INN- Adcetris 50mg injection. [Revised on 10 Jan 2023], [Accessed on 11 August 2023], www.ema.europa.eu/en/documents/product-information/www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf
4. Seattle Genetics, Inc. US Food & Drug Administration. [Revised Nov 2014], [Accessed on 11 August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_s056s078lbl.pdf

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.